Mark A. Meltz

Companies

• Lyell Immunopharma, Inc.General counsel Jun 11, 2025 to now¹
• Kinnate Biopharma Inc.Chief operating officer Dec 2, 2020 to Apr 5, 2024²
• Kinnate Biopharma Inc.General counsel Dec 2, 2020 to Apr 5, 2024²
• Audentes Therapeutics, Inc.General counsel Apr 1, 2019 to Jan 15, 2020³

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• KBKinnate Biopharma Inc.0 shares⁴Apr 3, 2024

As of each latest filing. The line shows shares held over time.

Recent filings

• Apr 3, 2024Returned to company 27,578 shares of Kinnate Biopharma Inc.⁴
• Mar 1, 2024Shares withheld for tax 558 shares at $2.59 of Kinnate Biopharma Inc.⁵
• Dec 1, 2023Shares withheld for tax 541 shares at $2.25 of Kinnate Biopharma Inc.⁶
• Sep 1, 2023Shares withheld for tax 541 shares at $2.35 of Kinnate Biopharma Inc.⁷
• Jun 1, 2023Shares withheld for tax 541 shares at $4.30 of Kinnate Biopharma Inc.⁸
• Mar 1, 2023Shares withheld for tax 638 shares at $5.21 of Kinnate Biopharma Inc.⁹
• Dec 1, 2022Shares withheld for tax 541 shares at $7.75 of Kinnate Biopharma Inc.¹⁰
• Sep 1, 2022Granted 25,000 shares of Kinnate Biopharma Inc.¹¹